STREAMLINE HEALTH SOLUTIONS(NASDAQ:STRM) stock Fundamental Analysis

Fundamental Rating

We assign a fundamental rating of 1 out of 10 to STRM. STRM was compared to 39 industry peers in the Health Care Technology industry. STRM may be in some trouble as it scores bad on both profitability and health. STRM does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

STRM had negative earnings in the past year.

STRM had a negative operating cash flow in the past year.

In multiple years STRM reported negative net income over the last 5 years.

In the past 5 years STRM always reported negative operating cash flow.

1.2 Ratios

STRM has a Return On Assets (-26.10%) which is in line with its industry peers.

STRM has a Return On Equity (-67.47%) which is comparable to the rest of the industry.

		Industry Rank	Sector Rank
ROA	-26.1%
ROE	-67.47%
ROIC	N/A

ROA(3y)-24.63%

ROA(5y)-13.26%

ROE(3y)-50.21%

ROE(5y)-27.25%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

With a Gross Margin value of 48.98%, STRM perfoms like the industry average, outperforming 43.24% of the companies in the same industry.

In the last couple of years the Gross Margin of STRM has declined.

The Profit Margin and Operating Margin are not available for STRM so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	48.98%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.81%

GM growth 5Y-4.29%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

STRM does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, STRM has less shares outstanding

The number of shares outstanding for STRM has been reduced compared to 5 years ago.

The debt/assets ratio for STRM is higher compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -4.79, we must say that STRM is in the distress zone and has some risk of bankruptcy.

STRM's Altman-Z score of -4.79 is on the low side compared to the rest of the industry. STRM is outperformed by 70.27% of its industry peers.

A Debt/Equity ratio of 0.72 indicates that STRM is somewhat dependend on debt financing.

STRM has a worse Debt to Equity ratio (0.72) than 75.68% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.72
Debt/FCF	N/A
Altman-Z	-4.79

ROIC/WACCN/A

WACC11%

2.3 Liquidity

STRM has a Current Ratio of 0.46. This is a bad value and indicates that STRM is not financially healthy enough and could expect problems in meeting its short term obligations.

STRM has a Current ratio of 0.46. This is amonst the worse of the industry: STRM underperforms 83.78% of its industry peers.

STRM has a Quick Ratio of 0.46. This is a bad value and indicates that STRM is not financially healthy enough and could expect problems in meeting its short term obligations.

STRM's Quick ratio of 0.46 is on the low side compared to the rest of the industry. STRM is outperformed by 83.78% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.46
Quick Ratio	0.46

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

STRM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 45.83%, which is quite impressive.

STRM shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -22.50%.

STRM shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 0.20% yearly.

EPS 1Y (TTM)45.83%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-190.7%

Revenue 1Y (TTM)-22.5%

Revenue growth 3Y25.8%

Revenue growth 5Y0.2%

Sales Q2Q%-27.95%

3.2 Future

Based on estimates for the next years, STRM will show a very strong growth in Earnings Per Share. The EPS will grow by 39.37% on average per year.

The Revenue is expected to decrease by -4.24% on average over the next years.

EPS Next Y93.2%

EPS Next 2Y39.37%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year-11.86%

Revenue Next 2Y-4.24%

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for STRM. In the last year negative earnings were reported.

Also next year STRM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

STRM's earnings are expected to grow with 39.37% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y39.37%

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

STRM does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

STREAMLINE HEALTH SOLUTIONS

NASDAQ:STRM (2/21/2025, 8:00:01 PM)

After market: 3.52 -0.08 (-2.22%)

3.6

0 (0%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Technology

Earnings (Last)12-12 2024-12-12/amc

Earnings (Next)06-09 2025-06-09

Inst Owners16.62%

Inst Owner Change-99.92%

Ins Owners18.45%

Ins Owner Change0.04%

Market Cap15.37M

Analysts82.86

Price TargetN/A

Short Float %0.8%

Short Ratio0.88

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)1

Avg Revenue beat(2)-8.62%

Min Revenue beat(2)-18.45%

Max Revenue beat(2)1.22%

Revenue beat(4)1

Avg Revenue beat(4)-5.76%

Min Revenue beat(4)-18.45%

Max Revenue beat(4)1.22%

Revenue beat(8)1

Avg Revenue beat(8)-4.89%

Revenue beat(12)5

Avg Revenue beat(12)0.97%

Revenue beat(16)7

Avg Revenue beat(16)1.44%

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)0%

EPS NQ rev (3m)0%

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)0%

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	0.83
P/FCF	N/A
P/OCF	N/A
P/B	1.1
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-1.95

EYN/A

EPS(NY)-0.11

Fwd EYN/A

FCF(TTM)-0.79

FCFYN/A

OCF(TTM)-0.63

OCFYN/A

SpS4.35

BVpS3.26

TBVpS-3.6

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-26.1%
ROE	-67.47%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	48.98%
FCFM	N/A

ROA(3y)-24.63%

ROA(5y)-13.26%

ROE(3y)-50.21%

ROE(5y)-27.25%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.81%

GM growth 5Y-4.29%

F-Score3

Asset Turnover0.52

Health

		Industry Rank	Sector Rank
Debt/Equity	0.72
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	14.57%
Cap/Sales	3.65%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	0.46
Quick Ratio	0.46
Altman-Z	-4.79

F-Score3

WACC11%

ROIC/WACCN/A

Cap/Depr(3y)43.1%

Cap/Depr(5y)69.7%

Cap/Sales(3y)7.87%

Cap/Sales(5y)12.75%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)45.83%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-190.7%

EPS Next Y93.2%

EPS Next 2Y39.37%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)-22.5%

Revenue growth 3Y25.8%

Revenue growth 5Y0.2%

Sales Q2Q%-27.95%

Revenue Next Year-11.86%

Revenue Next 2Y-4.24%

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y20.94%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year101.69%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y47.98%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y41.48%

OCF growth 3YN/A

OCF growth 5YN/A

STREAMLINE HEALTH SOLUTIONS (STRM) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens